| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Giovanni Amato, Gherardo Mazziotti, Mario Rotondi, Sergio Iorio, Mauro Doga, Francesca Sorvillo, Giovanni Manganella, Francesco Di Salle, Andrea Giustina, Carlo Carell. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical endocrinology. vol 56. issue 1. 2002-02-28. PMID:11849248. |
long-term effects of lanreotide sr and octreotide lar on tumour shrinkage and gh hypersecretion in patients with previously untreated acromegaly. |
2002-02-28 |
2023-08-12 |
Not clear |
| Britt Edén Engström, Pia Burman, F Anders Karlsso. Men with acromegaly need higher doses of octreotide than women. Clinical endocrinology. vol 56. issue 1. 2002-02-28. PMID:11849249. |
to investigate the effect of gender on the response of gh to short-acting octreotide in patients with acromegaly, and on the gh and igf-1 levels during long-term treatment with a slow-release formulation of octreotide. |
2002-02-28 |
2023-08-12 |
Not clear |
| Ulla Feldt-Rasmussen, Roger Abs, Bengt-Ake Bengtsson, Helge Bennmarker, Margareta Bramnert, Elizabeth Hernberg-Ståhl, John P Monson, Björn Westberg, Patrick Wilton, Christian Wüste. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European journal of endocrinology. vol 146. issue 1. 2002-02-25. PMID:11751070. |
to compare baseline characteristics in adult patients with growth hormone (gh) deficiency (ghd) who had previously been treated for cushing's disease or acromegaly with data from patients with ghd of other aetiologies. |
2002-02-25 |
2023-08-12 |
Not clear |
| M Blanco, S Bravo, T García-Caballero, C V Alvarez, R Gallego, A Lambert, G Morel, C Diéguez, A Beira. Localization of growth hormone receptors in rat and human thyroid cells. Cell and tissue research. vol 306. issue 3. 2002-02-06. PMID:11735043. |
it is well established that, in acromegaly, the thyroid gland is larger than normal and that gh increases triiodothyronin concentrations and decreases those of tetraiodothyronin (thyroxine). |
2002-02-06 |
2023-08-12 |
human |
| W M Drak. Experience with pegvisomant in the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527081. |
established modalities of therapy for acromegaly (surgical adenomectomy, external beam pituitary irradiation, oral dopamine agonists, and injectable somatostatin analogues) have as their common goal the lowering of circulating growth hormone (gh) levels, with a consequent reduction in serum insulin-like growth factor i (igf-i). |
2002-01-28 |
2023-08-12 |
Not clear |
| W M Drak. Experience with pegvisomant in the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527081. |
pegvisomant is a gh receptor antagonist that inhibits gh receptor dimerization and has a powerful ability to lower serum igf-i levels in patients with active acromegaly. |
2002-01-28 |
2023-08-12 |
Not clear |
| J J Kopchick, S Okad. Growth hormone receptor antagonists: discovery and potential uses. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527080. |
high levels of gh can lead to gigantism or a clinical syndrome termed acromegaly, and also have been implicated in diabetic eye and kidney damage. |
2002-01-28 |
2023-08-12 |
human |
| K M Morrison, Z Wu, M Bidlingmaier, C J Strasburge. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527090. |
growth hormone (gh) action induces a variety of biochemical factors of which insulin-like growth factor i (igf-i) is conventionally measured for the diagnosis and monitoring of gh-related disorders such as gh deficiency or acromegaly. |
2002-01-28 |
2023-08-12 |
Not clear |
| K M Morrison, Z Wu, M Bidlingmaier, C J Strasburge. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527090. |
in the treatment of active acromegaly with the gh receptor antagonist pegvisomant, als showed a closer correlation with the change in ring size, measured as a clinical indicator of disease activity, than did igf-i or igfbp-3. |
2002-01-28 |
2023-08-12 |
Not clear |
| D R Clemmon. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Hormone research. vol 55 Suppl 2. 2002-01-07. PMID:11684882. |
generally, studies have shown that igf-i is sensitive and specific for the diagnosis of acromegaly, but screening for gh deficiency (ghd) is less precise. |
2002-01-07 |
2023-08-12 |
Not clear |
| D Ferone, R Pivonello, S Lastoria, A Faggiano, M L Del Basso de Caro, P Cappabianca, G Lombardi, A Cola. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical endocrinology. vol 54. issue 4. 2002-01-03. PMID:11318782. |
gh and prl cosecretion frequently occurs in acromegaly and the sensitivity of both hormones to somatostatin analogs (sa) and dopamine agonists (da) alone or in combination, is still debated. |
2002-01-03 |
2023-08-12 |
Not clear |
| F Cordido, A Peñalva, T Martinez, F F Casanueva, C Diegue. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients. Clinical endocrinology. vol 54. issue 4. 2002-01-03. PMID:11318787. |
in acromegaly gh secretion is markedly increased due in most cases to a gh secreting pituitary adenoma. |
2002-01-03 |
2023-08-12 |
Not clear |
| W M Drake, C Parkinson, G M Besser, P J Traine. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends in endocrinology and metabolism: TEM. vol 12. issue 9. 2001-12-28. PMID:11595543. |
one such compound, b2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor i (igf-i), the principal mediator of gh action, in patients with acromegaly and to improve the symptoms and signs associated with gh excess. |
2001-12-28 |
2023-08-12 |
Not clear |
| W M Drake, C Parkinson, G M Besser, P J Traine. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends in endocrinology and metabolism: TEM. vol 12. issue 9. 2001-12-28. PMID:11595543. |
this article describes the mechanism of action of gh-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some of the challenges that lie ahead in judging the efficacy of a treatment that, unlike established therapies for acromegaly, does not aim to modify the underlying cause of acromegaly, namely excess gh secretion, but aims to lower serum igf-i levels to normal. |
2001-12-28 |
2023-08-12 |
Not clear |
| L Prieto, S M Web. Quality of life assessment in patients with GH deficiency and acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 12. 2001-12-28. PMID:11739478. |
quality of life assessment in patients with gh deficiency and acromegaly. |
2001-12-28 |
2023-08-12 |
Not clear |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
the relationship between serum gh and serum igf-i in acromegaly is gender-specific. |
2001-12-13 |
2023-08-12 |
human |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
in patients with acromegaly, there is a linear association between log10 serum gh and igf-i. |
2001-12-13 |
2023-08-12 |
human |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
we report the influence of gender on the relationship between serum gh and igf-i in subjects with active acromegaly. |
2001-12-13 |
2023-08-12 |
human |
| C Parkinson, W D Ryder, P J Traine. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701684. |
this study demonstrates a gender difference in the relationship between serum gh and igf-i in patients with active acromegaly consistent with relative gh resistance observed in normal and ghd females, which may, in part, be mediated by e. this observation has important implications for the use of igf-i as a measure of disease activity. |
2001-12-13 |
2023-08-12 |
human |
| T K Hansen, S Thiel, R Dall, A M Rosenfalck, P Trainer, A Flyvbjerg, J O Jørgensen, J S Christianse. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. The Journal of clinical endocrinology and metabolism. vol 86. issue 11. 2001-12-13. PMID:11701711. |
subsequently, we studied 30 healthy persons and 25 gh-deficient (ghd) patients randomized to treatment with gh or placebo in a double-blinded manner, and further included samples from 23 patients with active acromegaly examined before and after treatment with octreotide or the gh-receptor antagonist pegvisomant for 3 months. |
2001-12-13 |
2023-08-12 |
human |